SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+15.82%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$624M
AUM Growth
+$624M
(+5.5%)
Cap. Flow
-$56.5M
Cap. Flow
% of AUM
-9.04%
Top 10 Holdings %
Top 10 Hldgs %
57.01%
Holding
39
New
5
Increased
17
Reduced
15
Closed
2
Top Buys
| 1 |
Merck
MRK
|
$32.3M |
| 2 |
Johnson & Johnson
JNJ
|
$17.1M |
| 3 |
Biogen
BIIB
|
$14.8M |
| 4 |
Quest Diagnostics
DGX
|
$8.22M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$6.33M |
Top Sells
| 1 |
Baxter International
BAX
|
$41.3M |
| 2 |
Bristol-Myers Squibb
BMY
|
$27M |
| 3 |
Eli Lilly
LLY
|
$17.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$17.8M |
| 5 |
Takeda Pharmaceutical
TAK
|
$15.5M |
Sector Composition
| 1 | Healthcare | 99.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $62M | 9.93% | 965,433 -421,289 | -30% | -$27M |
|
2
Abbott
ABT
$231B
| $49.2M | 7.87% | 565,997 +28,737 | +5% | +$2.5M |
|
3
Boston Scientific
BSX
$156B
| $46.9M | 7.51% | 1,037,023 -71,313 | -6% | -$3.22M |
|
|
4
Merck
MRK
$210B
| $32.3M | 5.17% | +354,795 | New | +$32.3M |
|
|
5
Biogen
BIIB
$19.4B
| $30.3M | 4.86% | 102,219 +49,793 | +95% | +$14.8M |
|
|
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
| $30M | 4.8% | 387,580 -80,678 | -17% | -$6.24M |
|
7
Revvity
RVTY
$10.5B
| $29.9M | 4.79% | 308,099 +7,901 | +3% | +$767K |
|
8
Gilead Sciences
GILD
$140B
| $27M | 4.33% | 415,605 -59,451 | -13% | -$3.86M |
|
9
Incyte
INCY
$16.5B
| $24.7M | 3.95% | 282,542 -63,351 | -18% | -$5.53M |
|
10
Agilent Technologies
A
$35.7B
| $23.8M | 3.8% | 278,427 +18,134 | +7% | +$1.55M |
|
11
Elevance Health
ELV
$71.8B
| $23.1M | 3.7% | 76,508 +1,901 | +3% | +$574K |
|
12
Bruker
BRKR
$5.16B
| $17.4M | 2.79% | 341,750 +33,746 | +11% | +$1.72M |
|
|
13
Johnson & Johnson
JNJ
$427B
| $17.1M | 2.74% | +117,229 | New | +$17.1M |
|
14
Bio-Rad Laboratories Class A
BIO
$8.06B
| $16.6M | 2.66% | 44,870 -1,498 | -3% | -$554K |
|
15
Humana
HUM
$36.5B
| $16.6M | 2.66% | 45,261 +1,262 | +3% | +$463K |
|
16
Qiagen
QGEN
$10.1B
| $14.7M | 2.35% | 434,111 -50,490 | -10% | -$1.71M |
|
17
Perrigo
PRGO
$3.27B
| $14.1M | 2.26% | 272,644 +14,800 | +6% | +$765K |
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.6M | 2.19% | 126,164 +36,200 | +40% | +$3.92M |
|
19
United Therapeutics
UTHR
$13.8B
| $13.3M | 2.12% | 150,615 +2,468 | +2% | +$217K |
|
20
Ionis Pharmaceuticals
IONS
$6.79B
| $13.1M | 2.11% | 217,635 +86,121 | +65% | +$5.2M |
|
21
Elanco Animal Health
ELAN
$9.12B
| $12.8M | 2.04% | 433,477 +16,435 | +4% | +$484K |
|
22
Cardinal Health
CAH
$35.5B
| $10.8M | 1.72% | 212,563 +15,264 | +8% | +$772K |
|
|
23
Regeneron Pharmaceuticals
REGN
$61.5B
| $10.7M | 1.71% | 28,458 -47,377 | -62% | -$17.8M |
|
|
PDCO
24
DELISTED
Patterson Companies, Inc.
PDCO
| $9.78M | 1.57% | 477,355 +8,100 | +2% | +$166K |
|
25
Universal Health Services
UHS
$11.6B
| $9.45M | 1.51% | 65,864 +1,122 | +2% | +$161K |
|